Cellectis S.A. - American Depositary Shares (CLLS)

Bright Minds Biosciences develops serotonin-based therapeutics for neurological and neuropsychiatric conditions in a pre-clinical model.

ADMA Biologics develops plasma-derived therapies for immune deficiencies and infectious diseases, leveraging a vertically integrated model.

Structure Therapeutics advances oral therapies for diabetes, obesity, and pulmonary disease through its clinical-stage drug pipeline.

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday.

Cellectis reports strong Nature Communications data showing CssDNA boosts non-viral gene insertion efficiency and supports long-term therapeutic potential.

European American Depositary Receipts (ADRs) have recently experienced a period of significant fluctuation, reflecting a broader climate of market volatility that has ripple across global financial markets. While the general trend has seen some recent slips, the pharmaceutical sector, a traditionally defensive industry, has demonstrated a mixed performance, showcasing both

Let's have a look at what is happening on the US markets on Thursday. Below you can find the gap up and gap down stocks in today's session.

The US market session of Thursday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.

Gainers Dogwood Therapeutics (NASDAQ: DWTX) stock moved upwards by 80.1% to $9.94 during Monday's pre-market session. The market value of their outstanding shares is at $10.5 million.

U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Monday. Shares of Inventiva ADR (NASDAQ: IVA) fell sharply in today's pre-market trading following H1 results.

Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announced plans to acquire Merus for $8 billion in all-cash deal adding breakthrough therapy Petosemtamab to its late-stage pipeline.

Top 5 biotech stocks jumping into the top 10% momentum this week—ADCT, ARQT, CLLS, ENTO, HOTH—amid rapid sector rallies.

Here are the top movers in Friday's session, showcasing the stocks with significant price changes.